These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2005-000091-40||Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal – LSR) in the Treatment of Chronic Diabetic Foot Ulcers||2007-11-02||due-trials|
|Listed as ongoing, but also has a completion date||2007-003331-23||A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia||2009-07-09||bad-data|
|Listed as ongoing, but also has a completion date||2009-010865-22||An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich's ataxia.||2011-03-02||bad-data|
|Not reported||2012-000845-11||A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)||2016-10-21||due-trials|
|Completed, but no date Terminated||2013-002181-39||The efficacy and safety of Ferriprox® for the treatment of||bad-data|
|Not reported||2014-001427-79||Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)||2018-03-16||due-trials|
|Completed, but no date Terminated||2014-005685-30||Long-term safety and efficacy study of Ferriprox® for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias.||bad-data|
|Listed as ongoing, but also has a completion date||2015-004344-19||A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease||2019-09-04||bad-data|
|Completed, but no date||2018-004016-22||Safety and acceptability of deferiprone delayed release tablets in patients with systemic iron overload||bad-data|